Dataset Information

One day you'll wake up and won't have to go to work: The impact of changes in time use on mental health following retirement.

ABSTRACT: BACKGROUND:Retirement is a life transition involving an obligatory change in how people use their time. Because there are strong associations between use of time and health, different changes in time use following retirement may have different impacts on mental health. METHODS:105 participants were followed from 6 months before retirement to 12 months after retirement. At each time-point, use of time was quantified using a validated computerised 24-hour recall. Depression, anxiety and stress were assessed using the Depression, Anxiety and Stress Scales (DASS21), well-being with the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS), life satisfaction with the Australian Unity Personal Well-being Index (AUPWI), and self-esteem with the Rosenberg Self-Esteem Scale. Time-use data were analysed using compositional data analysis, which treats the 24-h day as a holistic "activity composition" rather than as individual activity domains. Time flow analytics were used to map patterns of change in time use from pre-retirement to post-retirement. Regression analysis was used to determine whether changes in the activity composition were significantly associated with changes in mental health. Compositional isotemporal substitution models were used to illustrate dose-response relationships between changes in time use and conditional changes in mental health for individual activity domains, such as sleep, screen time and physical activity. RESULTS:Following retirement, time no longer spent in work flowed mainly to household chores, sleep, screen time and quiet time (e.g. reading). Mental health improved overall. Changes in the activity composition were significantly related to conditional changes in DASS21 total score, depression, stress, and self-esteem, but not to anxiety, well-being or life satisfaction. Replacing work time with physical activity or sleep was associated with positive changes in mental health. Effect sizes for 60-minute substitutions ranged from -0.15 to +0.31. CONCLUSION:Following retirement, replacing work with physical activity, and to a lesser extent sleep, is associated with better mental health.

SUBMITTER: Olds T

PROVIDER: S-EPMC6023158 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

One day you'll wake up and won't have to go to work: The impact of changes in time use on mental health following retirement.

Olds Tim T Burton Nicola W NW Sprod Judy J Maher Carol C Ferrar Katia K Brown Wendy J WJ van Uffelen Jannique J Dumuid Dorothea D

PloS one 20180628 6

<h4>Background</h4>Retirement is a life transition involving an obligatory change in how people use their time. Because there are strong associations between use of time and health, different changes in time use following retirement may have different impacts on mental health.<h4>Methods</h4>105 participants were followed from 6 months before retirement to 12 months after retirement. At each time-point, use of time was quantified using a validated computerised 24-hour recall. Depression, anxiety ...[more]

PMID: 29953472

Similar Datasets

Project description:BackgroundOral artemisinin monotherapy (AMT), an important contributor to multi-drug resistant malaria, has been banned in Nigeria. While oral AMT has scarcely been found for several years now in other malaria-endemic countries, availability has persisted in Nigeria's private sector. In 2015, the ACTwatch project conducted a nationally representative outlet survey. Results from the outlet survey show the extent to which oral AMT prevails in Nigeria's anti-malarial market, and provide key product information to guide strategies for removal.ResultsBetween August 10th and October 3rd, 2015 a total of 13,480 outlets were screened for availability of anti-malarials and/or malaria blood testing services. Among the 3624 anti-malarial outlets, 33,539 anti-malarial products were audited, of which 1740 were oral AMT products, primarily artesunate (n = 1731). Oral AMT was imported from three different countries (Vietnam, China and India), representing six different manufacturers and 11 different brands. Availability of oral AMT was highest among pharmacies (84.0%) and Patent Propriety Medicine Vendors (drug stores, PPMVs) (38.7%), and rarely found in the public sector (2.0%). Oral AMT consisted of 2.5% of the national anti-malarial market share. Of all oral AMT sold or distributed, 52.3% of the market share comprised of a Vietnamese product, Artesunat®, manufactured by Mekophar Chemical Pharmaceutical Joint Stock Company. A further 35.1% of the market share were products from China, produced by three different manufacturers and 12.5% were from India by one manufacturer, Medrel Pharmaceuticals. Most of the oral AMT was distributed by PPMVs accounting for 82.2% of the oral AMT market share. The median price for a package of artesunate ($1.78) was slightly more expensive than the price of quality-assured (QA) artemether lumefantrine (AL) for an adult ($1.52). The median price for a package of artesunate suspension ($2.54) was three times more expensive than the price of a package of QA AL for a child ($0.76).ConclusionOral AMT is commonly available in Nigeria's private sector. Cessation of oral AMT registration and enforcement of the oral AMT ban for removal from the private sector are needed in Nigeria. Strategies to effectively halt production and export are needed in Vietnam, China and India.

Project description:BackgroundAbout one in five strokes occur during sleep (wake-up stroke). People with wake-up strokes have traditionally been considered ineligible for thrombolytic treatment because the time of stroke onset is unknown. However, some studies suggest that these people may benefit from recanalisation therapies.ObjectivesTo assess the effects of intravenous thrombolysis and other recanalisation therapies versus control in people with acute ischaemic stroke presenting on awakening.Search methodsWe searched the Cochrane Stroke Group Trials Register (last search: 9 January 2018). In addition, we searched the following electronic databases in December 2017: Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 11) in the Cochrane Library, MEDLINE, Embase, US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), the ISRCTN registry, and Stroke Trials Registry. We also screened references lists of relevant trials, contacted trialists, undertook forward tracking of relevant references, and contacted manufacturers of relevant devices and equipment.Selection criteriaRandomised controlled trials of intravenous thrombolytic drugs or intra-arterial therapies in people with acute ischaemic stroke presenting upon awakening.Data collection and analysisTwo review authors applied the inclusion criteria, extracted data, and assessed trial quality and risk of bias using the GRADE approach. We obtained both published and unpublished data.Main resultsWe included one pilot trial with nine participants. The trial was a feasibility trial that included participants with an unknown onset of stroke and signs on perfusion computed tomography of ischaemic tissue at risk of infarction, who were randomised to alteplase (0.9 mg/kg) or placebo. One trial was prematurely terminated due to signs of efficacy of the intervention arm; we did not include this trial because we were not able to obtain data for the portion of the participants with wake-up stroke after requesting this information from the trial authors. We identified six ongoing trials.Authors' conclusionsThere is insufficient evidence from randomised controlled trials for recommendations concerning recanalisation therapies for wake-up stroke. Results from ongoing trials will hopefully establish the efficacy and safety of such therapies.

Dataset Information

One day you'll wake up and won't have to go to work: The impact of changes in time use on mental health following retirement.

Publications

One day you'll wake up and won't have to go to work: The impact of changes in time use on mental health following retirement.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets